ΠΜΣ Μεταβολικά Νοσήματα των Οστών
Library of the School of Health Sciences

2019-02-28

2019

Giovanopoulos Ilias

Κασσή Ευανθία, Αναπληρώτρια Καθηγήτρια, Ιατρική, ΕΚΠΑ
Λυρίτης Γεώργιος, Ομότιμος Καθηγητής, Ιατρική, ΕΚΠΑ
Τριανταφυλλόπουλος Ιωάννης, Επίκουρος Καθηγητής, Ιατρική, ΕΚΠΑ

Καλσιμιμητικά / καλσιλυτικά φάρμακα: Ο τρόπος δράσης και ο ρόλος τους στην αντιμετώπιση μεταβολικών νοσημάτων των οστών

Greek

Calcimimetic / calcilytic drugs: Their action and role in the treatment of bone metabolic diseases

Calcium constitutes a critical element of the human organism. It is a fundamental structural element of the skeleton and takes part in many important cellular functions. The normal concentration of calcium in the organism is essential for both the intracellular and extracellular functions. In order to perform its basic functions, calcium needs to maintain a constant concentration in the blood (8.4 -10.4 mg/dL). Every fluctuation of calcium concentration is detected by the Calcium Sensing Receptor (CaSR), who regulates accordingly the production and secretion of the parathyroid hormone (PTH), which subsequently regulates Calcium’s extracellular level. Calcium Sensing Receptor, due to its implication at the regulation of Calcium levels in the organism, has been from the very first moment a target for the study and production of medications with regard to treat disorders that are related to calcium homeostasis imbalances and by extension to bone metabolism as well. Initially the research was contacted versus the generation of molecules that provoke stimulation of the CaSR receptor (stimulators or calcimimetics) and inhibition of PTH secretion, in order to manage disorders like primary hyperparathyroidism and subsequently secondary hyperparathyroidism in patients with Chronic Kidney Disease (CKD). In the same time, the idea of temporary secretion and release of the PTH in the main circulation aiming at the stimulation of the osteoblasts and the bone formation, function that was used for the study and production of medications such as tepiramide (Forsteo), led to the composition of molecules targeting at the inhibition of the Receptor CaSR (antagonists or calcilyitics) and at the stimulation of the secretion of PTH in the blood, that is to molecules that could potentially represent anabolic treatment in the management of osteoporosis, thus adding another arrow in the pharmaceutical quiver that we until now possess for the management of this systemic disease.

Health Sciences

Calcimimetics, Calcilytics, Hyperparathyroidism, CaSR, CKD

No

0

Yes

146

xii, 50

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2864507